Dan Zandberg

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dan Zandberg sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 4 completed early-phase tilt top decile by trial count

Dan Zandberg: 9 sponsored US clinical trials, 3 recruiting.

Dan Zandberg sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 3 trials.

Top-decile sponsor footprint

Dan Zandberg ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

NCT06052839
RECRUITING Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
RECRUITING Phase 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

NCT04080804
ACTIVE NOT RECRUITING Phase 2

HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

NCT04369937
ACTIVE NOT RECRUITING Phase 1

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

NCT04074967
COMPLETED Phase 2

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

NCT04326257
COMPLETED Phase 3

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
COMPLETED Phase 2

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

NCT02777385
COMPLETED Phase 2

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

NCT02289209

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7
Phase 3 1

Therapeutic Areas

Melanoma 3
HNSCC 2
NSCLC 2
Head and Neck Squamous Cell Carcinoma 2
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) 1
HPV-Related Squamous Cell Carcinoma 1
Head and Neck Squamous Cell Carcinoma (HNSCC) 1
Anal Cancer 1
Gastric Cancer 1
Cholangiocarcinoma 1

What is open in the Dan Zandberg pipeline

3 recruiting of 9 indexed (33% open); 4 completed (44%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Melanoma (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dan Zandberg: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Dan Zandberg sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Dan Zandberg4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Dan Zandberg sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dan Zandberg sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Dan Zandberg page

9 registered trials is a research-attention snapshot, not an endorsement of Dan Zandberg or any single study.

  • 3 of Dan Zandberg's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Melanoma is the condition Dan Zandberg studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Dan Zandberg pipeline card: 9 registered trials from official public datasets.Report a data error.